A Multicenter Phase 2 Trial of Pazopanib in Metastatic and Progressive Medullary Thyroid Carcinoma: MC057H

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

Samuel A. Wells, Bruce G. Robinson, Robert F. Gagel et al. · Journal of Clinical Oncology · 2011 · 1.5K citations · Full text

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

Rakesh Kumar, Victoria B. Knick, Sharon K. Rudolph et al. · Molecular Cancer Therapeutics · 2007 · 512 citations

Immunology, Pharmacotherapy, Bolus Administration +17

Phase II Study of Daily Sunitinib in FDG-PET–Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation

Laurie L. Carr, David A. Mankoff, Bernardo Goulart et al. · Clinical Cancer Research · 2010 · 417 citations · Full text

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study

Keith C. Bible, Vera J. Suman, Julian R. Molina et al. · The Lancet Oncology · 2010 · 414 citations · Full text

Thyroid Cancers, Oncology, Medicine +11

Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer

Elaine T. Lam, Matthew D. Ringel, Richard T. Kloos et al. · Journal of Clinical Oncology · 2010 · 373 citations